{
    "clinical_study": {
        "@rank": "114293", 
        "acronym": "HTN2DM", 
        "arm_group": {
            "arm_group_label": "Renal denervation therapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To demonstrate the efficacy of renal denervation therapy in treating resistant hypertension\n      and its effect on glucose metabolism in patients with type 2 diabetes mellitus"
        }, 
        "brief_title": "Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension, Resistant", 
            "Diabetes Mellitus", 
            "Renal Denervation Therapy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age ranges from 18 to 70 years inclusive\n\n          -  Essential hypertension\n\n          -  Office Systolic BP (SBP) \u2265 150 mmHg or Diastolic BP (DBP) \u2265 90mmHg\n\n          -  3 or more anti-hypertensive medications of different classes, including a diuretic,\n             or documented intolerance to multiple medications\n\n          -  Type 2 Diabetes Mellitus on oral hypoglycaemic agent (OHA)\n\n          -  2 functional kidneys; eGFR \u2265 45 mL/min/1.73m\u00b2 (MDRD formula)\n\n          -  Suitable renal anatomy compatible with the endovascular denervation procedure\n\n        Exclusion Criteria:\n\n          -  Individual has renal artery anatomy that is ineligible for treatment including:\n\n          -  Patients with secondary hypertension\n\n          -  Myocardial infarction, unstable angina pectoris, cerebrovascular accident within 6\n             months\n\n          -  Patient with type 1 diabetes mellitus\n\n          -  Patient on insulin due to oral drug failure\n\n          -  Renovascular abnormalities (including severe renal artery stenosis, previous renal\n             stenting or angioplasty, or known dual renal arteries)\n\n          -  Pregnancy\n\n          -  Patient with any implantable device incompatible with radiofrequency energy delivery\n\n          -  Hemodynamically significant valvular heart disease for which reduction of BP would be\n             considered hazardous\n\n          -  Any serious medical condition, which in the opinion of the investigator, may limit\n             the life expectancy of patients or adversely"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887067", 
            "org_study_id": "HKEC-2012-038"
        }, 
        "intervention": {
            "arm_group_label": "Renal denervation therapy", 
            "intervention_name": "Renal denervation therapy", 
            "intervention_type": "Procedure", 
            "other_name": "Renal denervation using Symplicity\u00ae Catheter System\u2122"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypertension", 
            "Diabetes Mellitus"
        ], 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "contact": {
                "email": "tsuikl1@ha.org.hk", 
                "last_name": "Kin Lam Tsui, FRCP (Edin, Glasg)", 
                "phone": "+852 25956412"
            }, 
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "Hong Kong"
                }, 
                "name": "Pamela Youde Nethersole Eastern Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Hong Kong"
        }, 
        "number_of_arms": "1", 
        "official_title": "Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "tsuikl1@ha.org.hk", 
            "last_name": "Kin Lam Tsui, FRCP (Edin, Glasg)", 
            "phone": "+852 25956412"
        }, 
        "overall_official": {
            "affiliation": "Pamela Youde Nethersole Eastern Hospital", 
            "last_name": "Kin Lam Tsui, FRCP (Edin, Glasg)", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in office systolic & diastolic blood pressure from baseline to 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887067"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Pamela Youde Nethersole Eastern Hospital", 
            "investigator_full_name": "Kin Lam TSUI", 
            "investigator_title": "Consultant Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in office systolic and diastolic blood pressure up to 3 years", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "HOMA-IR index at baseline, 3-month and 12-month", 
                "measure": "Change in insulin sensitivity", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in glucose metabolism", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Pamela Youde Nethersole Eastern Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pamela Youde Nethersole Eastern Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}